Scilex Holding to Present ELYXYB® Poster at 66th AHS Meeting in San Diego

Recent analyses highlight the struggle that many migraine sufferers face when using triptans, revealing that up to 60% of patients do not find them effective. In response to this unmet need, Scilex Holding Company has conducted a post-hoc analysis combining data from two Phase 3 trials to evaluate the efficacy of ELYXYB® (celecoxib oral solution) for those unresponsive to triptans.

The findings from these trials provide promising results for ELYXYB®. Among participants who had not experienced sufficient relief from triptans, 33.3% of those treated with ELYXYB® achieved complete pain relief within two hours, compared to just 14.3% in the placebo group. This significant improvement, statistically supported with a p-value of 0.0036, suggests that patients treated with ELYXYB® were three times more likely to achieve pain freedom than those given a placebo.

Dr. Richard B. Lipton, a prominent figure in headache research, will present these results at the 66th Annual Scientific Meeting of the American Headache Society in San Diego. Dr. Lipton, who serves as the Director of the Montefiore Headache Center and holds multiple professorships at the Albert Einstein College of Medicine, will detail the benefits of ELYXYB® for acute migraine treatment, especially for patients who do not respond well to triptans.

Scilex Holding Company focuses on developing non-opioid pain management solutions. Their portfolio includes several products aimed at addressing both acute and chronic pain conditions. One of their flagship products, ELYXYB®, is the only FDA-approved, ready-to-use oral solution for acute migraine treatment in adults. This new treatment could be a game-changer for many migraine sufferers, offering a viable alternative for those who find current treatments inadequate.

In addition to ELYXYB®, Scilex markets ZTlido®, a topical lidocaine product for neuropathic pain, and Gloperba®, an oral solution for gout flare prophylaxis. The company is also developing several other treatments, including SEMDEXA™ for sciatica, SP-103 for chronic neck pain, and SP-104 for fibromyalgia.

The company's commitment to non-opioid pain management solutions is driven by the need for safer, effective treatments for pain conditions. Their ongoing research and product development aim to provide new options for patients who have limited choices under current treatment paradigms.

Scilex's recent findings on ELYXYB® provide hope for migraine sufferers, particularly those who have found little relief with triptans. The company's innovative approaches and dedication to improving patient outcomes make it a significant player in the field of pain management. With continued research and development, Scilex aims to expand its impact, offering new and effective solutions for a range of pain-related conditions.